StockData
Lipella Pharmaceuticals Inc. logo

Lipella Pharmaceuticals Inc. (LIPO) stock

LIPOOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2025, quý kết thúc ngày Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 6/30
$0.00+0.00 (0.00%)

Close on Oct 19, 2026Market cap $2.27KP/E –Yield –

How the market prices Lipella Pharmaceuticals

Each ratio against its own distribution since 2022, from month-end prices and the figures reported at the time

Lipella Pharmaceuticals trades at 0.0× its earnings, against a median of 6.6× since 2022 — cheaper than 98% of the months in between.

The shaded bar covers the 5th to 95th percentile of month-end values since 2022, the darker part the 25th to 75th, the line the median and the dot today. The figure on the right is the percentile today sits at.

Price to sales since 2022

Median 6.6×, today 0.0×

What Lipella Pharmaceuticals keeps of every dollar

Trailing twelve months, from revenue down to net income. Grey columns are what comes out.

Margins against the industry

Operating margin-1387.9%vs -42.9%
EBITDA margin-1387.2%vs -29.3%
Pretax margin-1367.4%vs -13.0%
Net margin-1367.4%vs -39.9%

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

What it earns on the capital it uses

Trailing twelve months over average capital

Return on equity-361.8%vs -53.5%
Return on assets-236.4%vs -40.7%
Return on capital employed-316.9%vs -38.7%

How hard the assets work

Revenue per dollar of assets0.17vs 0.39
Revenue per employee$77.96Kvs $405.05K
Profit per employee-$1.07Mvs -$704.12K

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

What it owes and what covers it

Latest balance sheet, against twelve months of cash generation

Cash and short-term investments exceed every borrowing by $1.86M.

Cash and short-term investments$1.86M
EBITDA, trailing twelve months-$5.41M

Leverage and liquidity

Current ratio3.24vs 3.28
Quick ratio2.89vs 2.37

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

Scores and rules of thumb

Academic scores computed from the latest two fiscal years. They are screens, not verdicts.

Piotroski F-Score

Nine yes-or-no tests of profit, leverage and efficiency against last year.

3 of 9 tests passed

How the shares have traded

Total return includes reinvested dividends, to the close on Oct 19, 2026

Total return against the S&P 500

The axis is compressed: each step is ten times the one before, so a month and a decade fit on the same line.

LIPOS&P 500
PeriodLIPOS&P 500DifferenceLIPO per yearS&P 500 per year
1 month0.0%+0.6%−0.6 pts
3 months-98.5%+3.4%−101.8 pts
Year to date-99.7%+13.3%−113.0 pts
1 year-99.9%+16.6%−116.5 pts
3 years-100.0%+86.4%−186.4 pts-96.6%+23.1%

Who is betting against it

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M LIPO shares were sold short on Oct 30, 2026, down 0.1% from the previous report. At recent volumes it would take 1.9 days to buy them back. Over the last 20 sessions, 41.7% of the volume reported to FINRA was short selling.

Shares sold shortDays to cover

The last twelve reports

Settlement dateShares shortChangeAvg. daily volumeDays to cover
Oct 30, 20261,192-0.1%6181.9
Oct 15, 20261,1930.0%7551.6
Sep 30, 20261,1930.0%1,7321.0
Sep 15, 20261,193+9.2%7201.7
Aug 31, 20261,092-58.2%6,6941.0
Aug 14, 20262,615+3.9%4066.4
Jul 31, 20262,516+0.1%43,0171.0
Jul 15, 20262,513+0.1%40,6701.0
Jun 30, 20262,511+0.1%93,1571.0
Jun 15, 20262,509+0.5%126,4571.0
May 29, 20262,496-4.0%91,3991.0
May 15, 20262,599+0.3%32,0921.0

Every measure, in full

35 figures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings
–
Last ex-dividend date
No dividends
Fundamentals through
Sep 30, 2025
Share price as of
–

Share statisticsIndustry

Shares Change (YoY)
216.7%
11.0%
Shares Change (QoQ)
3.43%
0.57%
Float
4M
49M
Shares Held by Insiders
24.0%
11.3%

MarginsIndustry

Operating Margin
-1387.9%
-42.9%
Pretax Margin
-1367.4%
-13.0%
Profit Margin
-1367.4%
-39.9%
EBITDA Margin
-1387.2%
-29.3%

Returns on capitalIndustry

Return on Equity (ROE)
-361.8%
-53.5%
Return on Assets (ROA)
-236.4%
-40.7%
Return on Capital Employed (ROCE)
-316.9%
-38.7%

Financial positionIndustry

Current Ratio
3.24
3.28
Quick Ratio
2.89
2.37

GrowthIndustry

Revenue Growth (YoY)
-19.4%
5.68%
Revenue Growth (3Y CAGR)
27.4%
2.25%

EfficiencyIndustry

Asset Turnover
0.17
0.39
Revenue Per Employee
$77.96K
$405.05K
Profits Per Employee
-$1.07M
-$704.12K
Employee Count
5
75

Income statement (TTM)Industry

Revenue
$389.78K
$58.79M
Operating Income
-$5.41M
-$21.49M
Pretax Income
-$5.33M
-$14.83M
Net Income
-$5.33M
-$22.47M
EBITDA
-$5.41M
-$17.14M
EPS (Diluted)
-$2.42
-$0.83

Balance sheetIndustry

Net Cash (Debt)
$1.86M
$15.31M
Net Cash Per Share
$0.40
$0.72
Equity (Book Value)
$1.49M
$49.40M
Book Value Per Share
$0.32
$1.45
Tangible Book Value
$1.49M
$23.58M
Working Capital
$1.44M
$74.34M

Cash flow (TTM)Industry

Operating Cash Flow
-$4.78M
-$12.17M

Scores and fair valueIndustry

Piotroski F-Score
3
4

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?